BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $9926.HK readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06984718-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:AK104+lenvatinib readout (P2) · Akeso $9926.HK
DESCRIPTION:A Phase II Study of AK104 Combination With Lenvatinib Versus Le
 nvatinib for Second-line HCC\n\nPrimary completion date: 2026-11-30 (estim
 ated)\nPhase 2 · Oncology · HCC\, Hepatocellular Carcinoma\nEnrollment: 
 120 · Sites: 0\n\nPrimary completion = last participant's primary-endpoin
 t data collected\; topline results usually follow weeks to months later. S
 ponsor-reported\, often an estimate. Not investment advice.\n\nhttps://dat
 acutoff.com/radar.html?nct=NCT06984718\nhttps://clinicaltrials.gov/study/N
 CT06984718
URL:https://datacutoff.com/radar.html?nct=NCT06984718
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06767527-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:~AK112 readout (P3) · Akeso $9926.HK
DESCRIPTION:AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in
  Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer\n\n
 Primary completion date: 2026-12 (estimated) — month only\, shown on the
  1st\nPhase 3 · Oncology · Triple-Negative Breast Cancer (TNBC)\nEnrollm
 ent: 416 · Sites: 1\n\nPrimary completion = last participant's primary-en
 dpoint data collected\; topline results usually follow weeks to months lat
 er. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps:
 //datacutoff.com/radar.html?nct=NCT06767527\nhttps://clinicaltrials.gov/st
 udy/NCT06767527
URL:https://datacutoff.com/radar.html?nct=NCT06767527
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07436221-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20261227
DTEND;VALUE=DATE:20261228
SUMMARY:AK139 readout (P2) · Akeso $9926.HK
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of AK139 in Partici
 pants With Asthma\n\nPrimary completion date: 2026-12-27 (estimated)\nPhas
 e 2 · Respiratory · Asthma\nEnrollment: 160 · Sites: 2\n\nPrimary compl
 etion = last participant's primary-endpoint data collected\; topline resul
 ts usually follow weeks to months later. Sponsor-reported\, often an estim
 ate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07
 436221\nhttps://clinicaltrials.gov/study/NCT07436221
URL:https://datacutoff.com/radar.html?nct=NCT07436221
CATEGORIES:Respiratory,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05227664-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:AK117 readout (P2) · Akeso $9926.HK
DESCRIPTION:A Study of AK117/AK112 in Metastatic Triple-Negative Breast Can
 cer\n\nPrimary completion date: 2026-12-30 (estimated)\nOriginally planned
 : 2023-01-30 (+47.0 months)\nPhase 2 · Oncology · Metastatic Triple-nega
 tive Breast Cancer\, Locally Advanced Triple-negative Breast Cancer\nEnrol
 lment: 120 · Sites: 2\n\nPrimary completion = last participant's primary-
 endpoint data collected\; topline results usually follow weeks to months l
 ater. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttp
 s://datacutoff.com/radar.html?nct=NCT05227664\nhttps://clinicaltrials.gov/
 study/NCT05227664
URL:https://datacutoff.com/radar.html?nct=NCT05227664
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06951503-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270113
DTEND;VALUE=DATE:20270114
SUMMARY:AK112 readout (P3) · Akeso $9926.HK
DESCRIPTION:AK112 and Chemotherapy in First-line Metastatic Colorectal Canc
 er\n\nPrimary completion date: 2027-01-13 (estimated)\nPhase 3 · Oncology
  · Colorectal Adenocarcinoma\nEnrollment: 560 · Sites: 2\n\nPrimary comp
 letion = last participant's primary-endpoint data collected\; topline resu
 lts usually follow weeks to months later. Sponsor-reported\, often an esti
 mate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT0
 6951503\nhttps://clinicaltrials.gov/study/NCT06951503
URL:https://datacutoff.com/radar.html?nct=NCT06951503
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07755371-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:AK139 readout (P2) · Akeso $9926.HK
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of AK139 in Partici
 pants With Chronic Rhinosinusitis With Nasal Polyps\n\nPrimary completion 
 date: 2027-04-30 (estimated)\nPhase 2 · Other · Chronic Rhinosinusitis W
 ith Nasal Polyps (CRSwNP)\nEnrollment: 75 · Sites: 1\n\nPrimary completio
 n = last participant's primary-endpoint data collected\; topline results u
 sually follow weeks to months later. Sponsor-reported\, often an estimate.
  Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT077553
 71\nhttps://clinicaltrials.gov/study/NCT07755371
URL:https://datacutoff.com/radar.html?nct=NCT07755371
CATEGORIES:Other,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06928389-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:~NSCLC readout (P3) · Akeso $9926.HK
DESCRIPTION:Ivonescimab in Combination With Docetaxel in Advanced Non-Small
  Cell Lung Cancer\n\nPrimary completion date: 2027-05 (estimated) — mont
 h only\, shown on the 1st\nPhase 3 · Oncology · Non-Small Cell Lung Canc
 er\nEnrollment: 536 · Sites: 1\n\nPrimary completion = last participant's
  primary-endpoint data collected\; topline results usually follow weeks to
  months later. Sponsor-reported\, often an estimate. Not investment advice
 .\n\nhttps://datacutoff.com/radar.html?nct=NCT06928389\nhttps://clinicaltr
 ials.gov/study/NCT06928389
URL:https://datacutoff.com/radar.html?nct=NCT06928389
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07052253-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270510
DTEND;VALUE=DATE:20270511
SUMMARY:TT-00420 (tinengotinib) readout (P2) · Akeso $9926.HK
DESCRIPTION:A Phase II Clinical Study of AK104/AK112 in Combination With TT
 -00420 Tablet for Advanced HCC.\n\nPrimary completion date: 2027-05-10 (es
 timated)\nPhase 2 · Oncology · Hepatocellular Carcinoma (HCC)\nEnrollmen
 t: 100 · Sites: 1\n\nPrimary completion = last participant's primary-endp
 oint data collected\; topline results usually follow weeks to months later
 . Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps://
 datacutoff.com/radar.html?nct=NCT07052253\nhttps://clinicaltrials.gov/stud
 y/NCT07052253
URL:https://datacutoff.com/radar.html?nct=NCT07052253
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953999-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270514
DTEND;VALUE=DATE:20270515
SUMMARY:Ivonescimab\, AK117\, Albumin-bound Paclitaxel\, Gem… readout (P3
 ) · Akeso $9926.HK
DESCRIPTION:A Phase III Study of Ivonescimab + Chemo With/Without AK117 in 
 Metastatic Pancreatic Cancer\n\nPrimary completion date: 2027-05-14 (estim
 ated)\nPhase 3 · Oncology · Pancreatic Cancer\nEnrollment: 999 · Sites:
  3\n\nPrimary completion = last participant's primary-endpoint data collec
 ted\; topline results usually follow weeks to months later. Sponsor-report
 ed\, often an estimate. Not investment advice.\n\nhttps://datacutoff.com/r
 adar.html?nct=NCT06953999\nhttps://clinicaltrials.gov/study/NCT06953999
URL:https://datacutoff.com/radar.html?nct=NCT06953999
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06767540-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270710
DTEND;VALUE=DATE:20270711
SUMMARY:NCT06767540 readout (P3) · Akeso $9926.HK
DESCRIPTION:A Clinical Study of AK120 in Adolescents With Moderate-to-sever
 e Atopic Dermatitis\n\nPrimary completion date: 2027-07-10 (estimated)\nPh
 ase 3 · Immuno · Atopic Dermatitis\nEnrollment: 198 · Sites: 28\n\nPrim
 ary completion = last participant's primary-endpoint data collected\; topl
 ine results usually follow weeks to months later. Sponsor-reported\, often
  an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?
 nct=NCT06767540\nhttps://clinicaltrials.gov/study/NCT06767540
URL:https://datacutoff.com/radar.html?nct=NCT06767540
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07114315-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:~AK112 readout (P2) · Akeso $9926.HK
DESCRIPTION:A Study of AK130 in Combination With AK112 for the Treatment of
  Advanced Pancreatic Cancer\n\nPrimary completion date: 2027-08 (estimated
 ) — month only\, shown on the 1st\nPhase 2 · Oncology · Pancreatic Can
 cer\nEnrollment: 160 · Sites: 2\n\nPrimary completion = last participant'
 s primary-endpoint data collected\; topline results usually follow weeks t
 o months later. Sponsor-reported\, often an estimate. Not investment advic
 e.\n\nhttps://datacutoff.com/radar.html?nct=NCT07114315\nhttps://clinicalt
 rials.gov/study/NCT07114315
URL:https://datacutoff.com/radar.html?nct=NCT07114315
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07883213-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:~AK139 readout (P2) · Akeso $9926.HK
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of AK139 in Patient
 s With Prurigo Nodularis.\n\nPrimary completion date: 2027-08 (estimated) 
 — month only\, shown on the 1st\nPhase 2 · Immuno · Prurigo Nodularis 
 (PN)\nEnrollment: 132 · Sites: 0\n\nPrimary completion = last participant
 's primary-endpoint data collected\; topline results usually follow weeks 
 to months later. Sponsor-reported\, often an estimate. Not investment advi
 ce.\n\nhttps://datacutoff.com/radar.html?nct=NCT07883213\nhttps://clinical
 trials.gov/study/NCT07883213
URL:https://datacutoff.com/radar.html?nct=NCT07883213
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07669779-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:AK146D1 for injection readout (P2) · Akeso $9926.HK
DESCRIPTION:A Phase II Study of AK146D1 in Combination With AK112 in Advanc
 ed Non-Small Cell Lung Cancer\n\nPrimary completion date: 2027-08-30 (esti
 mated)\nPhase 2 · Oncology · Advanced Non Small Cell Lung Cancer (NSCLC)
 \nEnrollment: 348 · Sites: 1\n\nPrimary completion = last participant's p
 rimary-endpoint data collected\; topline results usually follow weeks to m
 onths later. Sponsor-reported\, often an estimate. Not investment advice.\
 n\nhttps://datacutoff.com/radar.html?nct=NCT07669779\nhttps://clinicaltria
 ls.gov/study/NCT07669779
URL:https://datacutoff.com/radar.html?nct=NCT07669779
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07591090-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:AK146D1 for injection readout (P2) · Akeso $9926.HK
DESCRIPTION:A Phase II Study of AK146D1 Combined With AK112 in Advanced Bre
 ast Cancer\n\nPrimary completion date: 2027-09-01 (estimated)\nPhase 2 · 
 Oncology · Advanced Breast Cancer\nEnrollment: 200 · Sites: 1\n\nPrimary
  completion = last participant's primary-endpoint data collected\; topline
  results usually follow weeks to months later. Sponsor-reported\, often an
  estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct
 =NCT07591090\nhttps://clinicaltrials.gov/study/NCT07591090
URL:https://datacutoff.com/radar.html?nct=NCT07591090
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06686030-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:~AK112 low dose readout (P2) · Akeso $9926.HK
DESCRIPTION:Combination Therapy of AK112 With Chemotherapy and/or Olaparib 
 in Platinum-sensitive Ovarian Cancer\n\nPrimary completion date: 2027-10 (
 estimated) — month only\, shown on the 1st\nPhase 2 · Oncology · Plati
 num-sensitive Ovarian Cancer\nEnrollment: 150 · Sites: 1\n\nPrimary compl
 etion = last participant's primary-endpoint data collected\; topline resul
 ts usually follow weeks to months later. Sponsor-reported\, often an estim
 ate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06
 686030\nhttps://clinicaltrials.gov/study/NCT06686030
URL:https://datacutoff.com/radar.html?nct=NCT06686030
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07502222-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:~AK139 and placebo readout (P2) · Akeso $9926.HK
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of AK139 in Patient
 s With Moderate-to-severe Atopic Dermatitis\n\nPrimary completion date: 20
 27-11 (estimated) — month only\, shown on the 1st\nPhase 2 · Immuno · 
 Moderate-to-Severe Atopic Dermatitis\nEnrollment: 168 · Sites: 0\n\nPrima
 ry completion = last participant's primary-endpoint data collected\; topli
 ne results usually follow weeks to months later. Sponsor-reported\, often 
 an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?n
 ct=NCT07502222\nhttps://clinicaltrials.gov/study/NCT07502222
URL:https://datacutoff.com/radar.html?nct=NCT07502222
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07449780-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20271117
DTEND;VALUE=DATE:20271118
SUMMARY:AK104(SC) readout (P3) · Akeso $9926.HK
DESCRIPTION:A Study of AK104 (SC) in Combination With Oxaliplatin and Capec
 itabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participant
 s With Unresectable Locally Advanced or Me…\n\nPrimary completion date: 
 2027-11-17 (estimated)\nPhase 3 · Oncology · Gastric / Gastroesophageal 
 Junction Adenocarcinoma\nEnrollment: 422 · Sites: 0\n\nPrimary completion
  = last participant's primary-endpoint data collected\; topline results us
 ually follow weeks to months later. Sponsor-reported\, often an estimate. 
 Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT0744978
 0\nhttps://clinicaltrials.gov/study/NCT07449780
URL:https://datacutoff.com/radar.html?nct=NCT07449780
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
